|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marin JF, Nunes RF, Coutinho AM, Zaniboni
EC, Costa LB, Barbosa FG, Queiroz MA, Cerri GG and Buchpiguel CA:
Theranostics in nuclear medicine: Emerging and Re-emerging
integrated imaging and therapies in the era of precision oncology.
Radiographics. 40:1715–1740. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Frangos S and Buscombe JR: Why should we
be concerned about a ‘g’? Eur J Nucl Med Mol Imaging. 46:5192019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pinzani P, D'Argenio V, Del Re M,
Pellegrini C, Cucchiara F, Salvianti F and Galbiati S: Updates on
liquid biopsy: Current trends and future perspectives for clinical
application in solid tumors. Clin Chem Lab Med. 59:1181–120. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crosby D: Delivering on the promise of
early detection with liquid biopsies. Br J Cancer. 126:313–315.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cona MM, Oyen R and Ni Y: Necrosis avidity
of organic compounds: A natural phenomenon with exploitable
theragnostic potentials. Curr Med Chem. 22:1829–1849. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Sun Z, Zhang J, Shao H, Cona MM,
Wang H, Marysael T, Chen F, Prinsen K, Zhou L, et al: A dual
targeting anticancer approach: Soil and seed principle. Radiology.
260:799–807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ni Y: Oncocidia: A small molecule dual
targeting pan-anticancer theragnostic strategy. Cancer Res.
74:17672014. View Article : Google Scholar
|
|
9
|
Siemann DW, Chaplin DJ and Walicke PA: A
review and update of the current status of the
vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Expert Opin Investig Drugs. 18:189–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ni Y, Huyghe D, Verbeke K, de Witte PA,
Nuyts J, Mortelmans L, Chen F, Marchal G, Verbruggen AM and Bormans
GM: First preclinical evaluation of mono-[123I]iodohypericin as a
necrosis avid tracer agent. Eur J Nucl Med Mol. 33:595–601. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cona MM, Feng YB, Verbruggen A, Oyen R and
Ni Y: Improve clearance of radioiodinated hypericin as a targeted
anticancer agent by using a duodenal drainage catheter in rats. Exp
Biol Med (Maywood). 238:1437–1449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Jiang C, Jiang X, Sun Z, Cona MM,
Liu W, Zhang J and Ni Y: Biliary and duodenal drainage for reducing
the radiotoxic risk of antineoplastic 131I-hypericin in
rat models. Exp Biol Med (Maywood). 240:1764–1773. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verburg FA, Flux G, Giovanella L, van
Nostrand D, Muylle K and Luster M: Differentiated thyroid cancer
patients potentially benefitting from postoperative I-131 therapy:
A review of the literature of the past decade. Eur J Nucl Med Mol
Imaging. 47:78–83. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Yin T, De Keyzer F, Feng YB, Chen
F, Liu JJ, Song SL, Yu J, Vandecaveye V, Swinnen J, et al:
Micro-HCCs in rats with liver cirrhosis: paradoxical targeting
effects with vascular disrupting agent CA4P. Oncotarget.
8:55204–55215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang S, Liu Y, Feng Y, Zhang J, Swinnen J,
Li Y and Ni Y: A review on curability of cancers: More efforts for
novel therapeutic options are needed. Cancers (Basel). 11:17822019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garon EB, Neidhart JD, Gabrail NY, de
Oliveira MR, Balkissoon J and Kabbinavar F: A randomized Phase II
trial of the tumor vascular disrupting agent CA4P (fosbretabulin
tromethamine) with carboplatin, paclitaxel, and bevacizumab in
advanced nonsquamous non-small-cell lung cancer. Onco Targets Ther.
9:7275–7283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Folkman J, Long DM Jr and Becker FF:
Growth and metastasis of tumor in organ culture. Cancer.
16:453–467. 1963. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sugimoto K, Kim SR, Imoto S, Tohyama M,
Kim SK, Matsuoka T, Yano Y, Kudo M and Hayashi Y: Characteristics
of hypo-vascular versus hypervascular well-differentiated
hepatocellular carcinoma smaller than 2 cm-focus on tumor size,
markers and imaging detectability. Dig Dis. 33:721–727. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hori K, Nishihara M, Shiraishi K and
Yokoyama M: The combretastatin derivative (Cderiv), a vascular
disrupting agent, enables polymeric nanomicelles to accumulate in
microtumors. J Pharm Sci. 99:2914–2925. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maeda H: Vascular permeability in cancer
and infection as related to macromolecular drug delivery, with
emphasis on the EPR effect for tumor-selective drug targeting. Proc
Jpn Acad Ser B Phys Biol Sci. 88:53–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ni Y: Treatment of avascular or
hypovascular micro-tumors. US Patent 16/628,904, Filed. July 4–2018
issued. January 10–2019.
|
|
22
|
Cacho-Díaz B, García-Botello DR,
Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sánchez E and
Herrera-Montalvo LA: Tumor microenvironment differences between
primary tumor and brain metastases. J Transl Med. 18:12020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Osako T: How can we better distinguish
metastatic tumors from primary tumors in the breast? Expert Rev
Anticancer Ther. 21:913–916. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim R, Keam B, Kim S, Kim M, Kim SH, Kim
JW, Kim YJ, Kim TM, Jeon YK, Kim DW, et al: Differences in tumor
microenvironments between primary lung tumors and brain metastases
in lung cancer patients: Therapeutic implications for immune
checkpoint inhibitors. BMC Cancer. 19:192021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ikarashi D, Okimoto T, Shukuya T, Onagi H,
Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S and
Carbone DP: Comparison of tumor microenvironments between primary
tumors and brain metastases in patients with NSCLC. JTO Clin Res
Rep. 2:1002302021.PubMed/NCBI
|
|
26
|
Pearce OM, Delaine-Smith RM, Maniati E,
Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones
RR, et al: Deconstruction of a metastatic tumor microenvironment
reveals a common matrix response in human cancers. Cancer Dis.
8:304–319. 2018. View Article : Google Scholar : PubMed/NCBI
|
